WO2022022716A1 - 抗tim3的单链抗体及其在制备治疗肿瘤的药物中的用途 - Google Patents
抗tim3的单链抗体及其在制备治疗肿瘤的药物中的用途 Download PDFInfo
- Publication number
- WO2022022716A1 WO2022022716A1 PCT/CN2021/109849 CN2021109849W WO2022022716A1 WO 2022022716 A1 WO2022022716 A1 WO 2022022716A1 CN 2021109849 W CN2021109849 W CN 2021109849W WO 2022022716 A1 WO2022022716 A1 WO 2022022716A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- chain antibody
- tim3
- nucleic acid
- seq
- cells
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001128—CD44 not IgG
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4633—Antibodies or T cell engagers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464428—CD44 not IgG
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464429—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2884—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the structure of the chimeric antigen receptor [CAR]
- A61K2239/11—Antigen recognition domain
- A61K2239/13—Antibody-based
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the structure of the chimeric antigen receptor [CAR]
- A61K2239/22—Intracellular domain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/47—Brain; Nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/00022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/00071—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
Definitions
- the present disclosure relates to the field of medical biotechnology, in particular, to a chimeric antigen receptor targeting TIM3, its encoding nucleic acid, expression vectors, cells, pharmaceutical compositions and uses thereof.
- Chimeric antigen receptor is a synthetic T cell receptor composed of an antigen binding domain, a transmembrane domain and an intracellular signaling domain.
- Antigen-binding domains are located outside the T cell membrane and include single-chain antibodies or ligands for specific binding to target antigens.
- the intracellular signaling domain is located in the T cell membrane and is used to transmit signals into the T cell to stimulate the T cell to generate an immune response.
- T cells expressing CAR can target and recognize target antigens on the surface of tumor cells, therefore, T cells expressing CAR can be used to target and kill tumor cells.
- the existing T cells expressing chimeric antigen receptor CAR are still weak in killing tumor cells.
- the purpose of the present disclosure is to overcome the problem that the existing T cells expressing chimeric antigen receptor CAR still have weak killing ability to tumor cells, and to provide an anti-TIM3 single-chain antibody.
- the present disclosure provides an anti-TIM3 single-chain antibody, and the amino acid sequence of the anti-TIM3 single-chain antibody includes the sequence shown in SEQ ID NO.1.
- the present disclosure provides a nucleic acid encoding the anti-TIM3 single-chain antibody of the first aspect; preferably, the nucleic acid has the nucleotide sequence shown in SEQ ID NO.2.
- the present disclosure provides a fusion protein comprising an antigen binding domain, a transmembrane domain and an intracellular signaling domain connected in sequence; the amino acid sequence of the intracellular signaling domain includes the first The amino acid sequence of the anti-TIM3 single-chain antibody in one aspect;
- the antigen binding domain includes an anti-CD44 single-chain antibody and/or an anti-CD133 single-chain antibody
- the intracellular signaling domain includes an anti-TIM3 single-chain antibody
- the fusion protein has the amino acid sequence shown in SEQ ID NO.3.
- the present disclosure provides a fusion nucleic acid encoding the fusion protein of the third aspect
- the fusion nucleic acid has the nucleotide sequence shown in SEQ ID NO.4.
- the present disclosure provides an expression vector into which an expression cassette is inserted, the expression cassette comprising a first nucleic acid fragment encoding an antigen-binding molecule and a second nucleic acid fragment encoding an intracellular signaling molecule, the The anti-TIM3 single-chain antibody of the first aspect is contained in the intracellular signaling molecule, and an IRES element or a 2A peptide coding sequence is inserted between the first nucleic acid fragment and the second nucleic acid fragment;
- the expression cassette is the fusion nucleic acid described in the fourth aspect.
- the present disclosure provides a chimeric antigen receptor-expressing cell obtained by transfecting a host cell with the expression vector described in the fifth aspect, the chimeric antigen receptor-expressing cell contains the anti-TIM3 single-chain antibody described in the first aspect.
- the host cells are T cells.
- the present disclosure provides the anti-TIM3 single-chain antibody of the first aspect, the nucleic acid of the second aspect, the fusion protein of the third aspect, the fusion nucleic acid of the fourth aspect, and the fifth aspect.
- the tumor is a brain glioma.
- the present disclosure provides a pharmaceutical composition, the active ingredient of which comprises the anti-TIM3 chimeric antigen receptor-expressing cell according to the sixth aspect.
- the anti-TIM3 single-chain antibody provided by the present disclosure can effectively improve the killing ability of T lymphocytes to tumor cells, so the T lymphocytes expressing the anti-TIM3 single-chain antibody can effectively kill tumor cells.
- Fig. 1 is a flow cytometer detection result diagram of CAR-T 1 cells provided in the embodiment of the present disclosure
- Fig. 2 is a flow cytometer detection result diagram of CAR-T 2 cells provided in the embodiment of the present disclosure
- Fig. 3 is a flow cytometer detection result diagram of CAR-T 3 cells provided in the embodiment of the present disclosure.
- the first aspect of the present disclosure provides an anti-TIM3 single-chain antibody, the amino acid sequence of the anti-TIM3 single-chain antibody includes the sequence shown in SEQ ID NO.1.
- SEQ ID NO.1 the sequence shown in SEQ ID NO.1 is as follows:
- T-cell immunoglobulin mucin-3 (TIM3) is an important tumor immune checkpoint, which is widely expressed on tumor-infiltrating T lymphocytes and can inhibit the tumor immune activity of tumor-infiltrating T lymphocytes.
- the anti-TIM3 single-chain antibody designed for TIM3 can effectively block the TIM3 pathway in T lymphocytes, enhance the tumor immune activity of T lymphocytes, and enhance the killing power of T lymphocytes on tumor cells.
- T lymphocytes expressing the above-mentioned anti-TIM3 single-chain antibody can effectively kill tumor cells.
- a second aspect of the present disclosure provides a nucleic acid encoding the anti-TIM3 single-chain antibody of the first aspect; preferably, the nucleic acid has the nucleotide sequence shown in SEQ ID NO.2.
- nucleotide sequence shown in SEQ ID NO.2 is as follows:
- a third aspect of the present disclosure provides a fusion protein comprising an antigen binding domain, a transmembrane domain and an intracellular signaling domain connected in sequence; the amino acid sequence of the intracellular signaling domain includes the first In one aspect, the amino acid sequence of the anti-TIM3 single chain antibody.
- the antigen binding domain includes an anti-CD44 single-chain antibody and/or an anti-CD133 single-chain antibody
- the intracellular signaling domain includes an anti-TIM3 single-chain antibody. More preferably, the fusion protein has the amino acid sequence shown in SEQ ID NO.3.
- the fusion protein shown in SEQ ID NO.3 is composed of anti-CD44 single-chain antibody, anti-CD133 single-chain antibody, CD28, CD3, T2A and anti-TIM3 single-chain antibody.
- amino acid sequence shown in SEQ ID NO.3 is as follows:
- a fourth aspect of the present disclosure provides a fusion nucleic acid encoding the fusion protein of the third aspect.
- the fusion nucleic acid has the nucleotide sequence shown in SEQ ID NO.4.
- nucleotide sequence shown in SEQ ID NO.4 is used to encode the amino acid sequence shown in SEQ ID NO.3.
- nucleotide sequence shown in SEQ ID NO.4 is as follows:
- a fifth aspect of the present disclosure provides an expression vector into which an expression cassette is inserted, the expression cassette comprising a first nucleic acid fragment encoding an antigen binding molecule and a second nucleic acid fragment encoding an intracellular signaling molecule, the The anti-TIM3 single-chain antibody described in the first aspect is contained in the intracellular signaling molecule, and an IRES element or a 2A peptide coding sequence is inserted between the first nucleic acid fragment and the second nucleic acid fragment; preferably, the The expression cassette is the fusion nucleic acid described in the fourth aspect.
- a sixth aspect of the present disclosure provides a chimeric antigen receptor-expressing cell obtained by transfecting a host cell with the expression vector described in the fifth aspect, the chimeric antigen receptor-expressing cell contains the anti-TIM3 single-chain antibody described in the first aspect.
- the host cells are T cells.
- the seventh aspect of the present disclosure provides the anti-TIM3 single-chain antibody of the first aspect, the nucleic acid of the second aspect, the fusion protein of the third aspect, the fusion nucleic acid of the fourth aspect, and the fifth aspect.
- the tumor is a brain glioma.
- An eighth aspect of the present disclosure provides a pharmaceutical composition, the active ingredient of which comprises the anti-TIM3 chimeric antigen receptor-expressing cell described in the sixth aspect.
- This example is used to illustrate the construction of the expression vector.
- nucleotide sequences shown in SEQ ID NO.4 and SEQ ID NO.5 were synthesized by using the full sequence synthesis method.
- the nucleotide sequence shown in SEQ ID NO.4 is used to encode the fusion protein shown in SEQ ID NO.3;
- the nucleotide sequence shown in SEQ ID NO.5 is used to encode the fusion shown in SEQ ID NO.6 protein.
- the composition of the fusion protein shown in SEQ ID NO.3 and SEQ ID NO.6 is as follows:
- G1 The fusion protein shown in SEQ ID NO.3 is composed of anti-CD44 single-chain antibody, anti-CD133 single-chain antibody, CD28, CD3, T2A and anti-TIM3 single-chain antibody;
- G2 The fusion protein shown in SEQ ID NO.6 is composed of anti-CD44 single-chain antibody, anti-CD133 single-chain antibody, CD28 and CD3.
- nucleotide sequence shown in SEQ ID NO.5 is as follows:
- amino acid sequence of the fusion protein shown in SEQ ID NO.6 is as follows:
- step (1) (2) Using pLVX-IRES- ⁇ NGFR (purchased from Clontech Company, the article number is 631982) as the vector, the two kinds of nucleotide sequences synthesized in step (1) were respectively inserted by conventional methods to obtain the two kinds of lentiviruses of this example Expression vector.
- This example is used to illustrate the preparation and detection of T cells expressing chimeric antigen receptors.
- Example 1 The two lentiviral expression vectors constructed in Example 1 and the pLVX-IRES- ⁇ NGFR empty vector were individually packaged with lentivirus, and then T cells were cultured, transfected and amplified in vitro according to the following methods.
- the medium was changed once until 2-4 weeks, and the transfected T lymphocytes CAR-T 1, CAR-T 2 and CAR-T 3 were obtained.
- CAR-T 1 is transfected with the nucleotide sequence shown in SEQ ID NO.4, and can express the fusion protein shown in SEQ ID NO.3;
- CAR-T 2 is transfected with the nucleotide sequence shown in SEQ ID NO.5
- the nucleotide sequence can express the fusion protein shown in SEQ ID NO. 6;
- CAR-T 3 is transfected with an empty vector.
- the detection method is as follows: centrifuge to collect the T cells to be detected after transfection, wash with PBS once, discard the supernatant, add the corresponding detection amount of monoclonal antibody according to the antibody instructions, protect from light for 30 minutes, wash and resuspend with PBS, and pass through the membrane.
- Flow cytometry was used for sandwich detection, and the antibody used in the detection was a mixture of His-tag-labeled CD44 and PE-labeled anti-His-tag antibody. The results are shown in Figures 1-3.
- Fig. 1 is a flow cytometer detection result diagram of CAR-T 1 cells provided in the embodiment of the present disclosure
- Fig. 2 is a flow cytometer detection result diagram of CAR-T 2 cells provided in the embodiment of the present disclosure
- Fig. 3 is a flow cytometer detection result diagram of CAR-T 3 cells provided in the embodiment of the present disclosure.
- This example is used to verify the killing ability of the CAR-T cells constructed in Example 2 on tumor cells.
- the three CAR-T cells transfected and cultured in Example 2 were taken and mixed with CD44 and CD133-positive glioma stem cells GSC20 according to different effector-target ratios (number of T cells: number of glioma stem cells).
- the mixed cells were placed in a 96-well plate for culture, wherein each well contained 4 ⁇ 10 4 glioma stem cells, and the reaction system per well was 200 ⁇ L.
- Culture conditions include: 37°C, 5% CO 2 , a saturated humidity incubator for 4 hours.
- Lysis rate % (OD in experimental group - OD spontaneously released by glioma stem cells - OD naturally released by effector cells)/(maximum OD released by glioma stem cells - OD spontaneously released by glioma stem cells)
- the anti-TIM3 single chain antibody provided by the present disclosure can effectively enhance the tumor immune activity of T lymphocytes and enhance the killing power of T lymphocytes to tumor cells.
- Example 3 The traditional second-generation CAR-T cells (EGFR vIII-CD28-CD3) targeting the classic tumor target EGFR vIII were used to replace the T cells in Example 3, and then the CARs with different effect-to-target ratios were detected according to the method of Example 3. -T killing rate of glioma stem cells GSC20.
- the test results are shown in Table 2.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明公开一种抗TIM3的单链抗体,该抗TIM3的单链抗体的氨基酸序列包括SEQ ID NO.1所示的序列。表达抗TIM3的单链抗体的T淋巴细胞能够有效杀伤肿瘤细胞。
Description
本公开涉及医药生物技术领域,具体地,涉及一种靶向TIM3的嵌合抗原受体、其编码核酸、表达载体、细胞、药物组合物和它们的用途。
嵌合抗原受体(Chimeric antigen receptor,CAR)是人工合成的T细胞受体,由抗原结合结构域、跨膜结构域和胞内信号传导结构域组成。抗原结合结构域位于T细胞膜外,包括单链抗体或配体,用于特异性地结合靶抗原。胞内信号传导结构域位于T细胞膜内,用于向T细胞内传导信号以刺激T细胞产生免疫反应。
CAR能够靶向识别肿瘤细胞表面的靶抗原,因此,表达CAR的T细胞能够用于靶向杀伤肿瘤细胞。然而,现有的表达嵌合抗原受体CAR的T细胞对肿瘤细胞的杀伤能力仍然较弱。
发明内容
本公开的目的是克服现有的表达嵌合抗原受体CAR的T细胞对肿瘤细胞的杀伤能力仍然较弱的问题,提供一种抗TIM3的单链抗体。
为了实现上述目的,第一方面,本公开提供一种抗TIM3的单链抗体,该抗TIM3的单链抗体的氨基酸序列包括SEQ ID NO.1所示的序列。
第二方面,本公开提供一种核酸,该核酸编码第一方面所述的抗TIM3的单链抗体;优选地,所述核酸具有SEQ ID NO.2所示的核苷酸序列。
第三方面,本公开提供一种融合蛋白,所述融合蛋白含有依次连接的抗原结合结构域、跨膜结构域和胞内信号传导结构域;所述胞内信号传导结构域的氨基酸序列包括第一方面所述的抗TIM3的单链抗体的氨基酸序 列;
优选地,所述抗原结合结构域包括抗CD44的单链抗体和/或抗CD133的单链抗体,所述胞内信号传导结构域包括抗TIM3的单链抗体;
更优选地,所述融合蛋白具有SEQ ID NO.3所示的氨基酸序列。
第四方面,本公开提供一种融合核酸,所述融合核酸编码第三方面所述的融合蛋白;
优选地,所述融合核酸具有SEQ ID NO.4所示的核苷酸序列。
第五方面,本公开提供一种表达载体,所述表达载体插入有表达框,所述表达框包括编码抗原结合分子的第一核酸片段和编码胞内信号传导分子的第二核酸片段,所述胞内信号传导分子中含有第一方面所述的抗TIM3的单链抗体,所述第一核酸片段与所述第二核酸片段之间插入有IRES元件或2A肽编码序列;
优选地,所述表达框为第四方面所述的融合核酸。
第六方面,本公开提供一种表达嵌合抗原受体的细胞,该表达嵌合抗原受体的细胞由宿主细胞转染第五方面所述的表达载体后得到,所述嵌合抗原受体中含有第一方面所述的抗TIM3的单链抗体。
可选地,所述宿主细胞为T细胞。
第七方面,本公开提供第一方面所述的抗TIM3的单链抗体、第二方面所述的核酸、第三方面所述的融合蛋白、第四方面所述的融合核酸、第五方面所述的表达载体、第六方面所述的表达嵌合抗原受体的细胞在制备治疗肿瘤的药物中的用途。
可选地,所述肿瘤为脑胶质瘤。
第八方面,本公开提供一种药物组合物,该药物组合物的有效成分包括第六方面所述的表达抗TIM3嵌合抗原受体的细胞。
通过上述技术方案,本公开提供的抗TIM3的单链抗体,能够有效提升T淋巴细胞对肿瘤细胞的杀伤能力,因此,表达抗TIM3的单链抗体的 T淋巴细胞能够有效杀伤肿瘤细胞。
本公开的其他特征和优点将在随后的具体实施方式部分予以详细说明。
附图是用来提供对本公开的进一步理解,并且构成说明书的一部分,与下面的具体实施方式一起用于解释本公开,但并不构成对本公开的限制。在附图中:
图1是本公开实施例提供的CAR-T 1细胞的流式细胞仪检测结果图;
图2是本公开实施例提供的CAR-T 2细胞的流式细胞仪检测结果图;
图3是本公开实施例提供的CAR-T 3细胞的流式细胞仪检测结果图。
以下结合附图对本公开的具体实施方式进行详细说明。应当理解的是,此处所描述的具体实施方式仅用于说明和解释本公开,并不用于限制本公开。
本公开的第一方面提供一种抗TIM3的单链抗体,该抗TIM3的单链抗体的氨基酸序列包括SEQ ID NO.1所示的序列。
其中,SEQ ID NO.1所示的序列如下所示:
T细胞免疫球蛋白粘蛋白-3(TIM3)是一个重要的肿瘤免疫检测点,广泛表达于肿瘤浸润T淋巴细胞上,能够抑制肿瘤浸润T淋巴细胞的肿瘤免疫活性。针对TIM3设计的抗TIM3的单链抗体,能够有效阻断T淋巴细 胞中的TIM3途径,提升T淋巴细胞的肿瘤免疫活性,增强T淋巴细胞对肿瘤细胞的杀伤力。
本公开的发明人发现,表达上述抗TIM3的单链抗体的T淋巴细胞能够有效杀伤肿瘤细胞。
本公开的第二方面提供一种核酸,该核酸编码第一方面所述的抗TIM3的单链抗体;优选地,所述核酸具有SEQ ID NO.2所示的核苷酸序列。
其中,SEQ ID NO.2所示的核苷酸序列如下所示:
本公开的第三方面提供一种融合蛋白,所述融合蛋白含有依次连接的抗原结合结构域、跨膜结构域和胞内信号传导结构域;所述胞内信号传导结构域的氨基酸序列包括第一方面所述的抗TIM3的单链抗体的氨基酸序列。优选地,所述抗原结合结构域包括抗CD44的单链抗体和/或抗CD133的单链抗体,所述胞内信号传导结构域包括抗TIM3的单链抗体。更优选地,所述融合蛋白具有SEQ ID NO.3所示的氨基酸序列。
其中,SEQ ID NO.3所示的融合蛋白由抗CD44的单链抗体、抗CD133的单链抗体、CD28、CD3、T2A和抗TIM3的单链抗体组成。
其中,SEQ ID NO.3所示的氨基酸序列如下所示:
本公开的第四方面提供一种融合核酸,所述融合核酸编码第三方面所述的融合蛋白。优选地,所述融合核酸具有SEQ ID NO.4所示的核苷酸序列。
其中,SEQ ID NO.4所示的核苷酸序列用于编码SEQ ID NO.3所示的氨基酸序列。
其中,SEQ ID NO.4所示的核苷酸序列如下所示:
本公开的第五方面提供一种表达载体,所述表达载体插入有表达框,所述表达框包括编码抗原结合分子的第一核酸片段和编码胞内信号传导分子的第二核酸片段,所述胞内信号传导分子中含有第一方面所述的抗TIM3的单链抗体,所述第一核酸片段与所述第二核酸片段之间插入有IRES元件或2A肽编码序列;优选地,所述表达框为第四方面所述的融合核酸。
本公开的第六方面提供一种表达嵌合抗原受体的细胞,该表达嵌合抗原受体的细胞由宿主细胞转染第五方面所述的表达载体后得到,所述嵌合抗原受体中含有第一方面所述的抗TIM3的单链抗体。可选地,所述宿主细胞为T细胞。
本公开的第七方面提供第一方面所述的抗TIM3的单链抗体、第二方面所述的核酸、第三方面所述的融合蛋白、第四方面所述的融合核酸、第五方面所述的表达载体、第六方面所述的表达嵌合抗原受体的细胞在制备治疗肿瘤的药物中的用途。可选地,所述肿瘤为脑胶质瘤。
本公开的第八方面提供一种药物组合物,该药物组合物的有效成分包括第六方面所述的表达抗TIM3嵌合抗原受体的细胞。
下面通过实施例来进一步说明本公开,但是本公开并不因此而受到任何限制。
实施例1
本实施例用于说明表达载体的构建。
(1)采用全序列合成方法,分别合成如SEQ ID NO.4和SEQ ID NO.5所示的核苷酸序列。SEQ ID NO.4所示的核苷酸序列用于编码SEQ ID NO.3所示的融合蛋白;SEQ ID NO.5所示的核苷酸序列用于编码SEQ ID NO.6所示的融合蛋白。其中,SEQ ID NO.3和SEQ ID NO.6所示的融合蛋白的组成如下:
G1:SEQ ID NO.3所示的融合蛋白由抗CD44的单链抗体、抗CD133的单链抗体、CD28、CD3、T2A和抗TIM3的单链抗体组成;
G2:SEQ ID NO.6所示的融合蛋白由抗CD44的单链抗体、抗CD133的单链抗体、CD28和CD3组成。
其中,SEQ ID NO.5所示的核苷酸序列如下所示:
SEQ ID NO.6所示的融合蛋白的氨基酸序列如下所示:
(2)采用pLVX-IRES-ΔNGFR(购自Clontech公司,货号为631982)作为载体,采用常规方法分别插入步骤(1)中合成的2种核苷酸序列,得到本实施例的2种慢病毒表达载体。
实施例2
本实施例用于说明表达嵌合抗原受体的T细胞的制备和检测。
(1)将实施例1构建的2种慢病毒表达载体和pLVX-IRES-ΔNGFR空载体分别进行慢病毒包装,然后按照下述方法分别进行T细胞的体外培养、转染和扩增。
(2)按照下述方法分离血液中的T细胞:将1mL无菌PBS与1mL血液混匀,然后缓慢加入到淋巴细胞分离液Ficoll的上层,并于4℃、400g条件下离心30min,加减速分别设置为0。离心结束后,去掉上层血浆,吸取中间白膜层细胞,加入PBS重悬洗涤,并于100g条件下离心10min,加减速正常。离心结束后,去掉上层洗涤液,加入1mL的1640+10%FBS+1%双抗+1×Glutamine培养基重悬细胞,然后利用抗人CD3/CD28磁珠(购自Thermo Fisher公司)刺激扩增,其中,重悬后细胞浓度为1×10
6细胞/mL,磁珠加入量为100μL,再加入100IU/mL rhIL-2(Peprotech),刺激培养2天,得到T细胞。
(3)按照下述方法进行慢病毒转染:取3份上述分离得到的T细胞,分别加入步骤(1)包装好的慢病毒,然后加入终浓度为6μg/mL的polybrene,混匀,并于32℃、800g的条件下离心100min。离心结束后放入培养箱中 继续培养24h。培养结束后将培养物于1500rpm的条件下离心15min,并将离心得到的细胞以1×10
6/mL的密度接种于培养板内,以rhIL2-100IU/mL刺激培养,以后每2-3天换液一次,直至2-4周,得到转染后的T淋巴细胞CAR-T 1、CAR-T 2和CAR-T 3。其中,CAR-T 1转染有SEQ ID NO.4所示的核苷酸序列,能够表达SEQ ID NO.3所示的融合蛋白;CAR-T 2转染有SEQ ID NO.5所示的核苷酸序列,能够表达SEQ ID NO.6所示的融合蛋白;CAR-T 3转染有空载体。
培养结束后,用PBS重悬细胞,并用流式细胞仪检测上述3种CAR-T细胞的比例及表面CAR蛋白的表达。检测方法为:分别离心收集转染后的待检测T细胞,PBS洗涤1次后弃上清,按抗体说明书加入相应检测量的单抗避光30min后,利用PBS洗涤、重悬,过膜后采用流式细胞仪进行夹心法检测,检测时使用的抗体为His-tag标记的CD44和PE标记的抗His-tag的抗体的混合物。结果如图1~3所示。
图1是本公开实施例提供的CAR-T 1细胞的流式细胞仪检测结果图;
图2是本公开实施例提供的CAR-T 2细胞的流式细胞仪检测结果图;
图3是本公开实施例提供的CAR-T 3细胞的流式细胞仪检测结果图。
从图1和图2可以看出,CAR-T 1细胞和CAR-T 2细胞中均检测出区别于正常T淋巴细胞的其它细胞;由图3可以看出,CAR-T 3细胞并未检测出区别于正常T淋巴细胞的其它细胞。由此说明本实施例中转染有融合基因的CAR-T细胞均已成功表达目标融合蛋白。
实施例3
本实施例用于验证实施例2构建的CAR-T细胞对肿瘤细胞的杀伤能力。
分别取实施例2中转染并培养得到的3种CAR-T细胞,分别与CD44和CD133阳性的胶质瘤干细胞GSC20按照不同的效靶比(T细胞数量: 胶质瘤干细胞数量)混合。将混合后的细胞置于96孔板中进行培养,其中,每孔中含有胶质瘤干细胞4×10
4个,每孔反应体系为200μL。培养条件包括:37℃,5%CO
2,饱和湿度孵箱孵育4小时。
乳酸脱氢酶活性测定:离心结束后,每孔吸取上清液100μL置于96孔酶标板中,同时,每孔加入100μL LDH底物,室温避光反应30min。反应结束后,每孔加50μL终止液终止酶促反应。在酶标仪490nm测定光密度值(OD)。计算各组平均光密度值(OD),按下式计算每种T细胞对胶质瘤干细胞的裂解率。结果如表1所示。
裂解率%=(实验组OD-胶质瘤干细胞自发释放OD-效应细胞自然释放OD)/(胶质瘤干细胞最大释放OD-胶质瘤干细胞自发释放OD)
表1
由表1可以看出,本公开提供的抗TIM3的单链抗体能够有效提升T淋巴细胞的肿瘤免疫活性,增强T淋巴细胞对肿瘤细胞的杀伤力。
对比例
采用靶向经典肿瘤靶点EGFR vIII的传统第二代CAR-T细胞(EGFR vIII-CD28-CD3)替换实施例3中的T细胞,然后按照实施例3的方法检测不同效靶比下该CAR-T对胶质瘤干细胞GSC20的杀伤率。检测结果见表2。
表2
由表2可以看出,靶向经典肿瘤干细胞靶点EGFR vIII的传统第二代CAR-T细胞对胶质瘤干细胞的杀伤力不如本公开提供的表达抗TIM3的单链抗体的T细胞。
以上结合附图详细描述了本公开的优选实施方式,但是,本公开并不限于上述实施方式中的具体细节,在本公开的技术构思范围内,可以对本公开的技术方案进行多种简单变型,这些简单变型均属于本公开的保护范围。
另外需要说明的是,在上述具体实施方式中所描述的各个具体技术特征,在不矛盾的情况下,可以通过任何合适的方式进行组合,为了避免不必要的重复,本公开对各种可能的组合方式不再另行说明。
此外,本公开的各种不同的实施方式之间也可以进行任意组合,只要其不违背本公开的思想,其同样应当视为本公开所公开的内容。
Claims (10)
- 一种抗TIM3的单链抗体,其特征在于,该抗TIM3的单链抗体的氨基酸序列包括SEQ ID NO.1所示的序列。
- 一种核酸,其特征在于,该核酸编码权利要求1所述的抗TIM3的单链抗体;优选地,所述核酸具有SEQ ID NO.2所示的核苷酸序列。
- 一种融合蛋白,其特征在于,所述融合蛋白含有依次连接的抗原结合结构域、跨膜结构域和胞内信号传导结构域;所述胞内信号传导结构域的氨基酸序列包括权利要求1所述的抗TIM3的单链抗体的氨基酸序列;优选地,所述抗原结合结构域包括抗CD44的单链抗体和/或抗CD133的单链抗体,所述胞内信号传导结构域包括抗TIM3的单链抗体;更优选地,所述融合蛋白具有SEQ ID NO.3所示的氨基酸序列。
- 一种融合核酸,其特征在于,所述融合核酸编码权利要求3所述的融合蛋白;优选地,所述融合核酸具有SEQ ID NO.4所示的核苷酸序列。
- 一种表达载体,其特征在于,所述表达载体插入有表达框,所述表达框包括编码抗原结合分子的第一核酸片段和编码胞内信号传导分子的第二核酸片段,所述胞内信号传导分子中含有权利要求1所述的抗TIM3的单链抗体,所述第一核酸片段与所述第二核酸片段之间插入有IRES元件或2A肽编码序列;优选地,所述表达框为权利要求4所述的融合核酸。
- 一种表达嵌合抗原受体的细胞,其特征在于,该表达嵌合抗原受体的细胞由宿主细胞转染权利要求5所述的表达载体后得到,所述嵌合抗原受体中含有权利要求1所述的抗TIM3的单链抗体。
- 根据权利要求6所述的细胞,其特征在于,所述宿主细胞为T细胞。
- 权利要求1所述的抗TIM3的单链抗体、权利要求2所述的核酸、权利要求3所述的融合蛋白、权利要求4所述的融合核酸、权利要求5所述的表达载体、权利要求6或7所述的表达嵌合抗原受体的细胞在制备治疗肿瘤的药物中的用途。
- 根据权利要求8所述的用途,其中,所述肿瘤为脑胶质瘤。
- 一种药物组合物,其特征在于,该药物组合物的有效成分包括权利要求6或7所述的表达抗TIM3嵌合抗原受体的细胞。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP21849058.9A EP4174089A1 (en) | 2020-07-31 | 2021-07-30 | Anti-tim3 single-chain antibody and use thereof in preparing medicine for treating tumors |
US18/018,711 US20230295294A1 (en) | 2020-07-31 | 2021-07-30 | Anti-tim3 single-chain antibody and use thereof in preparing medicine for treating tumor |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010760969.4A CN113214396B (zh) | 2020-07-31 | 2020-07-31 | 抗tim3的单链抗体及其在制备治疗肿瘤的药物中的用途 |
CN202010760969.4 | 2020-07-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022022716A1 true WO2022022716A1 (zh) | 2022-02-03 |
Family
ID=77085785
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2021/109849 WO2022022716A1 (zh) | 2020-07-31 | 2021-07-30 | 抗tim3的单链抗体及其在制备治疗肿瘤的药物中的用途 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20230295294A1 (zh) |
EP (1) | EP4174089A1 (zh) |
CN (1) | CN113214396B (zh) |
WO (1) | WO2022022716A1 (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114316050B (zh) * | 2021-12-24 | 2022-11-11 | 北京市神经外科研究所 | Cd133抗体、嵌合抗原受体及其应用 |
CN114213537B (zh) * | 2021-12-24 | 2022-06-14 | 北京市神经外科研究所 | Cd133抗体、嵌合抗原受体及其应用 |
CN114213538B (zh) * | 2021-12-24 | 2022-07-08 | 北京市神经外科研究所 | Cd44抗体、嵌合抗原受体及其应用 |
TW202345900A (zh) * | 2022-03-14 | 2023-12-01 | 大陸商正大天晴藥業集團南京順欣製藥有限公司 | 抗tim-3抗體與去甲基化藥物的藥物組合 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018156434A1 (en) * | 2017-02-22 | 2018-08-30 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Tim3-binding chimeric antigen receptors |
CN109451741A (zh) * | 2016-04-12 | 2019-03-08 | 西福根有限公司 | 抗tim-3抗体及组合物 |
CN109735500A (zh) * | 2019-01-25 | 2019-05-10 | 苏州茂行生物科技有限公司 | 一种分泌型靶向cd133的car-t细胞及其制备方法和应用 |
WO2019232444A1 (en) * | 2018-05-31 | 2019-12-05 | Washington University | Chimeric antigen receptor t cells (car-t) for the treatment of cancer |
CN110621698A (zh) * | 2017-04-05 | 2019-12-27 | 西福根有限公司 | 靶向pd-1、tim-3及lag-3的组合疗法 |
CN110938146A (zh) * | 2019-11-20 | 2020-03-31 | 华中农业大学 | Tim-3单域抗体及其应用 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8841418B2 (en) * | 2011-07-01 | 2014-09-23 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to TIM3 |
JP2018510151A (ja) * | 2015-03-06 | 2018-04-12 | ソレント・セラピューティクス・インコーポレイテッド | Tim3に結合する抗体医薬 |
EP3356411B1 (en) * | 2015-10-02 | 2021-06-30 | F. Hoffmann-La Roche AG | Bispecific antibodies specific for pd1 and tim3 |
JP7027401B2 (ja) * | 2016-07-14 | 2022-03-01 | ブリストル-マイヤーズ スクイブ カンパニー | Tim3に対する抗体およびその使用 |
WO2019046321A1 (en) * | 2017-08-28 | 2019-03-07 | Bristol-Myers Squibb Company | TIM-3 ANTAGONISTS FOR THE TREATMENT AND DIAGNOSIS OF CANCERS |
CN110042126A (zh) * | 2018-01-16 | 2019-07-23 | 北京卡替医疗技术有限公司 | 一种包含超级增强型til细胞的免疫细胞药物 |
CN108794630A (zh) * | 2017-12-18 | 2018-11-13 | 镇江爱必梦生物科技有限公司 | 鼠抗人tim3蛋白单克隆抗体制备及其免疫组化用途 |
KR20200108870A (ko) * | 2018-01-12 | 2020-09-21 | 브리스톨-마이어스 스큅 컴퍼니 | Tim3에 대한 항체 및 그의 용도 |
EP3740506A1 (en) * | 2018-01-16 | 2020-11-25 | Bristol-Myers Squibb Company | Methods of treating cancer with antibodies against tim3 |
CN110144011B (zh) * | 2018-02-14 | 2020-06-23 | 上海洛启生物医药技术有限公司 | 针对t淋巴细胞免疫球蛋白黏蛋白3的单域抗体 |
-
2020
- 2020-07-31 CN CN202010760969.4A patent/CN113214396B/zh active Active
-
2021
- 2021-07-30 US US18/018,711 patent/US20230295294A1/en active Pending
- 2021-07-30 EP EP21849058.9A patent/EP4174089A1/en active Pending
- 2021-07-30 WO PCT/CN2021/109849 patent/WO2022022716A1/zh unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109451741A (zh) * | 2016-04-12 | 2019-03-08 | 西福根有限公司 | 抗tim-3抗体及组合物 |
WO2018156434A1 (en) * | 2017-02-22 | 2018-08-30 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Tim3-binding chimeric antigen receptors |
CN110621698A (zh) * | 2017-04-05 | 2019-12-27 | 西福根有限公司 | 靶向pd-1、tim-3及lag-3的组合疗法 |
WO2019232444A1 (en) * | 2018-05-31 | 2019-12-05 | Washington University | Chimeric antigen receptor t cells (car-t) for the treatment of cancer |
CN109735500A (zh) * | 2019-01-25 | 2019-05-10 | 苏州茂行生物科技有限公司 | 一种分泌型靶向cd133的car-t细胞及其制备方法和应用 |
CN110938146A (zh) * | 2019-11-20 | 2020-03-31 | 华中农业大学 | Tim-3单域抗体及其应用 |
Also Published As
Publication number | Publication date |
---|---|
US20230295294A1 (en) | 2023-09-21 |
CN113214396A (zh) | 2021-08-06 |
EP4174089A1 (en) | 2023-05-03 |
CN113214396B (zh) | 2022-04-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2022022716A1 (zh) | 抗tim3的单链抗体及其在制备治疗肿瘤的药物中的用途 | |
US20210363258A1 (en) | Hpv-specific binding molecules | |
WO2022022718A1 (zh) | 抗cd133的单链抗体及其在制备治疗肿瘤的药物中的用途 | |
JP2021525509A (ja) | 細胞療法のための多様な抗原結合ドメイン、新規プラットフォームおよびその他の強化 | |
EP3877054B1 (en) | Process for producing genetically engineered t cells | |
JP2021168667A (ja) | 操作された造血幹細胞/前駆細胞及び非tエフェクター細胞、ならびにその使用 | |
CN108474002A (zh) | 用于转导的方法、反应剂盒、反应剂和设备 | |
WO2019237900A1 (zh) | 携带截短或未截短的髓样细胞触发性受体信号结构的嵌合抗原受体及其应用 | |
JP7491532B2 (ja) | HvG疾患の処置における使用のためのCAR | |
CN116057181A (zh) | 用于修饰和递送淋巴细胞的方法和组合物 | |
US20210317408A1 (en) | Methods and compositions for genetically modifying lymphocytes in blood or in enriched pbmcs | |
WO2022033057A1 (zh) | 一种基于单域抗体的bcma嵌合抗原受体及其应用 | |
WO2022222846A1 (zh) | 靶向cd19的嵌合抗原受体、制备方法及其应用 | |
WO2020047527A2 (en) | Methods and compositions for genetically modifying lymphocytes in blood or in enriched pbmcs | |
BR112020016030A2 (pt) | Células t car e doenças autoimunes | |
CN116209764A (zh) | 感染、活化及扩增免疫细胞的方法及组合物 | |
WO2022022719A1 (zh) | IL7Rα的截短体及其在制备治疗肿瘤的药物中的用途 | |
WO2022022720A1 (zh) | 抗cd44的单链抗体及其在制备治疗肿瘤的药物中的用途 | |
CN113045675B (zh) | 一种抗cd22蛋白分子的抗体及其应用 | |
CN113045676B (zh) | 一种抗cd19蛋白分子的抗体及其应用 | |
CN116143943A (zh) | 一种靶向baffr嵌合抗原受体、car-t细胞及应用 | |
WO2023272924A1 (zh) | 新型全人源抗人b7h3抗体和嵌合抗原受体及其用途 | |
CN117247462B (zh) | 一种靶向ror1的嵌合抗原受体、car-t细胞及其用途 | |
US20220048978A1 (en) | Cr3022 chimeric antigen receptors and methods of use | |
WO2024032247A1 (zh) | 一种cll1抗体及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21849058 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2021849058 Country of ref document: EP Effective date: 20230127 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |